Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
XPO1 inhibitor
DRUG CLASS:
XPO1 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
selinexor (47)
KPT-8602 (5)
CBS9106 (1)
selinexor (47)
KPT-8602 (5)
CBS9106 (1)
›
Associations
(53)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
selinexor
Sensitive: A1 - Approval
selinexor
Sensitive
:
A1
selinexor
Sensitive: A1 - Approval
selinexor
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
selinexor
Sensitive: A1 - Approval
selinexor
Sensitive
:
A1
selinexor
Sensitive: A1 - Approval
selinexor
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
selinexor + pomalidomide
Sensitive: A2 - Guideline
selinexor + pomalidomide
Sensitive
:
A2
selinexor + pomalidomide
Sensitive: A2 - Guideline
selinexor + pomalidomide
Sensitive
:
A2
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
selinexor + daratumumab
Sensitive: A2 - Guideline
selinexor + daratumumab
Sensitive
:
A2
selinexor + daratumumab
Sensitive: A2 - Guideline
selinexor + daratumumab
Sensitive
:
A2
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
selinexor + carfilzomib
Sensitive: A2 - Guideline
selinexor + carfilzomib
Sensitive
:
A2
selinexor + carfilzomib
Sensitive: A2 - Guideline
selinexor + carfilzomib
Sensitive
:
A2
Chr del(17p)
Multiple Myeloma
Chr del(17p)
Multiple Myeloma
bortezomib + selinexor
Sensitive: B - Late Trials
bortezomib + selinexor
Sensitive
:
B
bortezomib + selinexor
Sensitive: B - Late Trials
bortezomib + selinexor
Sensitive
:
B
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
No biomarker
Liposarcoma
No biomarker
Liposarcoma
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
GRM1 overexpression
Liposarcoma
GRM1 overexpression
Liposarcoma
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
CALB1 underexpression
Liposarcoma
CALB1 underexpression
Liposarcoma
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
CALB1 deletion
Liposarcoma
CALB1 deletion
Liposarcoma
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
TP53 wild-type
Endometrial Cancer
TP53 wild-type
Endometrial Cancer
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
selinexor
Sensitive: B - Late Trials
selinexor
Sensitive
:
B
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
KPT-8602
Sensitive: B - Late Trials
KPT-8602
Sensitive
:
B
KPT-8602
Sensitive: B - Late Trials
KPT-8602
Sensitive
:
B
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
selinexor
Sensitive: C2 – Inclusion Criteria
selinexor
Sensitive
:
C2
selinexor
Sensitive: C2 – Inclusion Criteria
selinexor
Sensitive
:
C2
NRAS mutation
Multiple Myeloma
NRAS mutation
Multiple Myeloma
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
RAS mutation
Multiple Myeloma
RAS mutation
Multiple Myeloma
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
KRAS mutation
Multiple Myeloma
KRAS mutation
Multiple Myeloma
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
KPT-8602
Sensitive: C3 – Early Trials
KPT-8602
Sensitive
:
C3
KPT-8602
Sensitive: C3 – Early Trials
KPT-8602
Sensitive
:
C3
IDH2 R172K
Acute Myelogenous Leukemia
IDH2 R172K
Acute Myelogenous Leukemia
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
pembrolizumab + selinexor
Sensitive
:
C3
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
pembrolizumab + selinexor
Sensitive
:
C3
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
pembrolizumab + selinexor
Sensitive
:
C3
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
pembrolizumab + selinexor
Sensitive
:
C3
NRAS mutation
Colorectal Cancer
NRAS mutation
Colorectal Cancer
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
pembrolizumab + selinexor
Sensitive
:
C3
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
pembrolizumab + selinexor
Sensitive
:
C3
Chr del(17p)
Multiple Myeloma
Chr del(17p)
Multiple Myeloma
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
DOCK8 mutation
Glioblastoma
DOCK8 mutation
Glioblastoma
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
EP400 mutation
Glioblastoma
EP400 mutation
Glioblastoma
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
PDX1 mutation
Glioblastoma
PDX1 mutation
Glioblastoma
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
Chr t(11;14)
Multiple Myeloma
Chr t(11;14)
Multiple Myeloma
venetoclax + selinexor
Sensitive: C3 – Early Trials
venetoclax + selinexor
Sensitive
:
C3
venetoclax + selinexor
Sensitive: C3 – Early Trials
venetoclax + selinexor
Sensitive
:
C3
PTGS2 expression
Rectal Cancer
PTGS2 expression
Rectal Cancer
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
CD177 expression
Rectal Cancer
CD177 expression
Rectal Cancer
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
TP53 mutation
Myelodysplastic Syndrome
TP53 mutation
Myelodysplastic Syndrome
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
selinexor
Sensitive: C3 – Early Trials
selinexor
Sensitive
:
C3
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
CBS9106
Sensitive: C4 – Case Studies
CBS9106
Sensitive
:
C4
CBS9106
Sensitive: C4 – Case Studies
CBS9106
Sensitive
:
C4
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
KPT-8602
Sensitive: D – Preclinical
KPT-8602
Sensitive
:
D
KPT-8602
Sensitive: D – Preclinical
KPT-8602
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login